SeqWright Announces the Addition of Illumina HiSeq 2000 to its Next Generation Sequencing Capabilities
8/18/2010 8:30:52 AM
HOUSTON, Aug. 17 /PRNewswire/ -- SeqWright Inc., a world-wide leader in custom genomic and molecular biology services, announced today that it has acquired the Illumina HiSeq 2000 Next Generation Sequencing System. Addition of the HiSeq 2000 platform enables SeqWright to perform the largest and most complex sequencing studies at the lowest possible cost to its customers. The ability to process increased numbers of samples and to decode larger and more complex genomes means that virtually any sequencing project is now achievable. SeqWright will utilize Illumina's efficient and scalable data analysis software to transform billions of bases of raw sequencing data into publishable, biologically meaningful results.
Addition of the Illumina HiSeq 2000 to SeqWright's already established Roche 454 GS FLX Titanium and AB SOLiD 4 next generation sequencing platforms, along with multiple available sequence capture and target enrichment technologies, enables SeqWright to offer its customers the very best in sequencing solutions. For target enrichment, SeqWright recently introduced its RainDance Technology capabilities as well as Certified Service Provider status for Agilent Sureselect. SeqWright is also an Authorized Service Provider for NimbleGen capture Arrays. With its proficiency in next generation genomics and a strong commitment to investing in next-gen technologies, SeqWright is proving to be a leader in the life science industry, with a wealth of experience and a comprehensive portfolio of services. SeqWright's primary focus is to offer customer-specific solutions while continuing to evaluate the market for the next advancement in Next Generation platforms.
Based in Houston, TX, SeqWright Incorporated is recognized as an international leader in the field of contract genomic services, including next generation sequencing. For over fifteen years, SeqWright has provided state-of-the-art Molecular Biology and Genomic services, from small projects up to full clinical trials. SeqWright was recently awarded a license by the state of California to operate as a clinical laboratory. This license, along with CLIA certification, allows SeqWright to handle clinical samples from the vast majority of the United States. For additional information about SeqWright and its services, please visit www.seqwright.com.
SOURCE SeqWright, Inc.